[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

15h ago

PremiumPress Releases

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

6d ago

PremiumThe Fly

FDA approves Genentech’s Alecensa for adjuvant treatment

6d ago

PremiumThe Fly

Roche announces data from its Phase III OCARINA II study of OCREVUS

7d ago

PremiumThe Fly

Genentech reports data from OCARINA II study of Ocrevus

7d ago

PremiumPress Releases

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

8d ago

PremiumThe Fly

Roche price target raised to CHF 260 from CHF 250 at Morgan Stanley

8d ago

More RHHVF News >

0QOK News on the Web

2024-04-24

Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump

CNBC

Neutral

2024-04-19

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Yahoo Finance

Neutral

2024-04-18

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Yahoo Finance

Neutral

2024-04-18

UBS Sticks to Its Hold Rating for Roche Holding AG (RHHVF)

TipRanks News

Neutral

2024-04-17

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Yahoo Finance

Neutral

2024-04-17

Here are the top 15 companies in Singapore to work for, according to LinkedIn

CNBC

Neutral

2024-04-15

Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

Yahoo Finance

Neutral

2024-04-15

Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

Yahoo Finance

Neutral

News Score - Last 7 Days

Neutral

GB:0QOK

Sector Average

Media Buzz

This Week4 articles

Weekly Average3 articles

News Sentiment

This Week50%

Sector Average58%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is GB:0QOK’s Media Buzz Sentiment?

4 articles about GB:0QOK were published this week. In an average week, 3 articles are published.

What is GB:0QOK’s weekly average amount of articles?

In an average week, 3 articles about GB:0QOK are published.

What is GB:0QOK’s News Sentiment?

50% of articles about GB:0QOK were positive this week, compared to its sector average of 58%.

Healthcare Stocks that are Trending in the News

DAWNDay One Biopharmaceuticals

IMVTImmunovant

RVVRevive Therapeutics

NVSNovartis

ISRGIntuitive Surgical

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing